KAILERA THERAPEUTICS INC
KLRA · NASDAQ
Updated at 2026-10-13 14:35:20
- Today's High
- $11.44
- Today’s Low
- $11.04
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $11.39
- Previous Close
- $11.33
- Volume
- 1.22M
- Market Cap
- $1.46B
- P/E Ratio
- --
- EPS
- --
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 180 THIRD AVENUE, WALTHAM, MA, UNITED STATES, 02451
- Country
- US
- Listing Date
- 2026-04-17
- Fiscal Year End
- December
- Shares Outstanding
- 129.57M
- CIK
- --
- Website
- www.kailera.com
Kailera Therapeutics, Inc. is a cutting-edge biotechnology company dedicated to developing innovative gene therapies for rare genetic diseases, addressing critical unmet medical needs. Utilizing its proprietary platform, Kailera aims to enhance the precision and effectiveness of therapeutic interventions across various genetic disorders. Backed by a strong intellectual property portfolio and strategic collaborations with premier research institutions, the company is poised to emerge as a leader in the gene therapy sector. As it progresses with a promising pipeline of products, Kailera Therapeutics is committed to delivering long-term value for its investors while significantly improving patient outcomes.
Financial Metrics
Revenue
2026-06-30
$0
2026-03-31
$0
2025-06-30
$0
2025-03-31
$0
Operating Expenses
2026-06-30
$121.37M
2026-03-31
$84.66M
2025-06-30
$30.65M
2025-03-31
$20.45M
Net Income
2026-06-30
-$111.3M
2026-03-31
-$78.86M
2025-06-30
-$28.94M
2025-03-31
-$17.98M
Net Profit Margin
2026-06-30
--
2026-03-31
--
2025-06-30
--
2025-03-31
--
Earnings Per Share
2026-06-30
$-1.09
2026-03-31
$-3.65
2025-06-30
--
2025-03-31
--
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$111.2M
2026-03-31
-$84.55M
2025-06-30
-$30.58M
2025-03-31
-$20.39M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-06-30
--
2025-03-31
--
| Item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Expenses | $121.37M | $84.66M | $30.65M | $20.45M |
| Net Income | -$111.3M | -$78.86M | -$28.94M | -$17.98M |
| Net Profit Margin | -- | -- | -- | -- |
| Earnings Per Share | $-1.09 | $-3.65 | -- | -- |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$111.2M | -$84.55M | -$30.58M | -$20.39M |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.